Shernan Holtan, Chief of Blood and Marrow Transplantation and Professor of Medicine at Roswell Park Comprehensive Cancer Center, shared a post on LinkedIn:
“It’s go time for CD83!
Today is a big day for Roswell Park Comprehensive Cancer Center and a step toward the end of AML. We’ve opened our clinical trial of CD83 CAR T cells for relapsed/refractory AML.
This is translational science in action: patient samples → mechanism → engineered therapy → first-in-human evaluation, all made possible by an outstanding team spanning clinical care, lab science, apheresis and cell processing, GMP manufacturing, clinical research operations, data management, and our regulatory, quality, and compliance partners.”
More from Shernan Holtan on OncoDaily.